James J. Driscoll, MD, PhD, and James Ignatz-Hoover, MD, PhD, share a perspective on a study published recently in ONCOLOGY.
ONCOLOGY Vol 37, Issue 4
“Even in well-resourced countries, there are disparities in exposure to treatments; some of these are rooted deeply in social determinants of health and represent a very complex problem of providing equal access.”
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma
ByDaniel V. T. Catenacci, MD,Yoon-Koo Kang, MD, PhD,Hope E. Uronis, MD, MHS,Keun-Wook Lee, MD, PhD,Matthew C. H. Ng, MD,Peter C. Enzinger, MD,Se Hoon Park, MD, PhD,Philip J. Gold, MD,Jill Lacy, MD,Howard S. Hochster, MD,Sang Cheul Oh, MD, PhD,Yeul Hong Kim, MD, PhD,Kristen A. Marrone, MD,Ronan J. Kelly, MD,Rosalyn A. Juergens, MD,Jong Gwang Kim, MD, PhD,Thierry Alcindor, MD, MSc,Sun Jin Sym, MD, PhD,Eun-Kee Song, MD, PhD,Cheng Ean Chee, MD,Yee Chao, MD, PhD,Sunnie Kim, MD,Do-Youn Oh, MD, PhD,Jennifer Yen, PhD,Justin I. Odegaard, MD, PhD,Errin Lagow, PhD,Daner Li, MS,Jichao Sun, PhD,Patrick Kaminker, PhD,Paul A. Moore, PhD,Minori Koshiji Rosales, MD, PhD,Haeseong Park, MD, MPH
Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Zhubin J. Gahvari, MD, MS, and Natalie S. Callander, MD, provide a comprehensive overview of current treatment paradigms in relapsed and refractory multiple myeloma.
Co-editor-in-Chief Julie M. Vose, MD, MBA, writes about the effects and prevalence of burnout amongst oncologists and reviews strategies to address the issue.
Advertisement
Advertisement
Trending on CancerNetwork
1
KRd Appears to Exhibit Greater Outcomes in Standard-Risk Multiple Myeloma
2
KRd-Based Quadruplets May “Eliminate” Transplant Need for Multiple Myeloma
3
Creating a “Watershed Moment” for Novel Therapeutic Access in Lymphoma
4
FDA Grants FTD to WTX-124 in Advanced Pretreated Cutaneous Melanoma
5
